HGH Fragment 176-191 Side Effects

Reported HGH Fragment 176-191 side effects

HGH Fragment 176-191 / AOD-9604 has been reported as well tolerated in Phase 1 and Phase 2 trials, with side effects that were mostly mild and self-limiting. However, "well tolerated in a Phase 2 trial that failed its primary endpoint" is a different safety claim than the data underlying approved chronic-use medications, and long-term safety of off-label subcutaneous AOD-9604 in healthy adults is essentially unstudied. Reported side effects from clinical trials: Injection-site reactions — for subcutaneous administration, mild redness, itching, or small induration at the injection site. Typically resolves over hours to days. Rotate injection sites. Headache — mild, transient, reported in a minority of subjects. Mild gastrointestinal symptoms — nausea, abdominal discomfort, occasional loose stools, particularly with oral formulations. Fatigue — reported in some subjects; unclear if substance-related or reflective of caloric restriction in the context of a weight-loss trial. Pruritus — occasional generalised itching. Laboratory monitoring (from trial data): IGF-1: not significantly raised at therapeutic doses, consistent with the separation-of-function design. Fasting glucose and insulin: no significant derangement in short-term trials. Liver enzymes (ALT, AST): no significant elevation. Complete blood count: no significant changes. Lipid profile: modest favourable changes in some trials (small reductions in triglycerides, total cholesterol), but these were not consistent across trials. Side effects commonly reported in community use (not from controlled trials): Mild lightheadedness or flushing shortly after injection in sensitive users. Appetite changes (either suppression or, paradoxically, increased hunger in some users). Sleep changes — most users report no effect; a minority report mild sleep disruption. Temporary drop in energy during the first week or two of a cycle, often attributed to concurrent caloric restriction rather than AOD-9604 itself. Long-term safety concerns. The longest clinical trial of AOD-9604 was approximately 24 weeks. Long-term (years) safety data do not exist. Potential concerns that remain hypothetical but unresolved: Long-term effects on adipose tissue homeostasis. Chronic lipolytic stimulation could theoretically alter adipocyte number, size, or function in ways that have not been characterised. The trials did not follow subjects long enough to detect such effects. Receptor desensitisation or adaptive changes. The molecular target of AOD-9604 has not been definitively identified, making it difficult to predict receptor-level adaptations with chronic use. Effects on endogenous hGH/IGF-1 axis. Short-term data suggest no impact, but chronic effects have not been studied. Unknown effects in disease populations (diabetes, hepatic impairment, renal impairment, cardiovascular disease) — trial populations were typically healthy obese adults without significant comorbidities. Drug interactions — not systematically characterised. Quality-of-product concerns. For users sourcing AOD-9604 from the research-peptide market, the actual substance purity and identity are unverifiable without third-party HPLC/mass spectrometry testing. Contamination with endotoxin, residual solvents, or other peptides is possible. Mislabeling (wrong peptide entirely) has been documented in peptide testing studies of research-chemical vendors. Using a compound whose identity and purity are uncertain adds risk beyond what the mechanism-of-action or clinical trial data describe. When to stop and seek medical attention: Severe injection-site reaction (expanding redness, warmth, tenderness suggesting infection) Allergic reaction (rash, hives, swelling, difficulty breathing) Chest pain, palpitations, or shortness of breath Any new unexplained symptom you would take seriously on a prescription medication Weight loss associated with systemic symptoms (fever, night sweats, lymphadenopathy — think about alternative diagnoses)

When to continue, reduce, or stop HGH Fragment 176-191

HGH Fragment 176-191 contraindications

Absolute contraindications: Pregnancy. No safety data in pregnant women. Avoid. Breastfeeding. No data on peptide passage into breast milk or effects on nursing infants. Avoid. Paediatric use (under 18). AOD-9604 was developed and tested in adults. Effects on paediatric growth, development, and long-term health are unknown. Avoid outside of any hypothetical supervised paediatric research protocol (there are essentially none). Active malignancy. While AOD-9604 does not measurably raise IGF-1 (unlike full-length hGH or strong GH secretagogues), the long-term effects on cancer biology are not known. In active cancer or recent cancer history, err on the side of not adding an unregulated off-label peptide. Known hypersensitivity to AOD-9604 or any component of the formulation (including benzyl alcohol preservative in bacteriostatic water). Relative contraindications (discuss with physician before use): Diabetes (type 1 or type 2). Short-term trials did not show glucose derangement from AOD-9604 alone, but diabetic users stacking AOD-9604 with GH secretagogues (CJC-1295, ipamorelin, tesamorelin) must monitor glucose carefully, as GH stimulation can worsen insulin resistance. Cardiovascular disease. Stable CAD, prior MI, heart failure, arrhythmias — insufficient data to establish safety of chronic AOD-9604 use. Discuss with cardiologist. Uncontrolled hypertension. Optimise BP control before adding any off-label compound. Untreated thyroid dysfunction. Ensure thyroid status is known and optimised before attributing body composition issues to AOD-9604 "fixing." Hepatic or renal impairment. Lack of pharmacokinetic data in these populations. Psychiatric illness on medication. Interactions not characterised. Eating disorders (anorexia, bulimia, orthorexia). Using weight-loss peptides in the context of eating-disordered thinking can worsen the disorder. A different therapeutic approach is appropriate. BMI <25 without genuine medical indication. Using a "fat loss" peptide for aesthetic body recomposition when BMI is already in the healthy range is not evidence-based and shifts the risk-benefit calculation unfavourably. Drug-specific considerations: GLP-1 agonists (semaglutide, tirzepatide, liraglutide): no known dangerous interaction; the combination is unlikely to add meaningful benefit over GLP-1 alone. GH and GH secretagogues: additive metabolic effects; monitor glucose and IGF-1. Insulin and oral hypoglycaemics: monitor glucose if any suspicion of dosing effect. Thyroid hormones: monitor thyroid panel. Corticosteroids: corticosteroids promote central adiposity and insulin resistance; adding AOD-9604 does not neutralise these effects. Athlete considerations: As of 2026, AOD-9604 is included on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone-related substance or growth-hormone fragment. Competitive athletes subject to anti-doping testing should NOT use AOD-9604 — it will result in a failed test and sanctions. Verify current WADA status with your national anti-doping agency; the Prohibited List is updated annually. Travel considerations: AOD-9604 is not an approved medicine in most jurisdictions. Travelling internationally with unregulated peptides can create customs and legal issues. In the US, possession of research chemicals for personal use exists in a grey zone; however, crossing international borders with peptides can be classified as importation, which has different legal implications. Regulatory status reminder: Not FDA-approved for any indication. Not EMA-approved. Not approved by any major Western regulatory agency. Failed its pivotal Phase 2b trial for obesity. Has been used historically in some compounding pharmacy preparations, with tightening US regulatory restrictions. Often sold as research chemical with no therapeutic claims. When to stop immediately and seek medical attention: Signs of allergic reaction (rash, swelling, difficulty breathing). Severe injection-site reaction with signs of infection (expanding redness, warmth, fever). Chest pain, palpitations, or shortness of breath. New unexplained weight loss with systemic symptoms (consider alternative diagnosis). Any symptom you would take seriously on a prescription medication. The bottom line: AOD-9604 is a peptide with interesting preclinical biology that failed its pivotal clinical trial for obesity and has never been approved as a medicine. Users attracted to it for fat loss should first exhaust evidence-based options (GLP-1 agonists, structured diet/exercise programs, bariatric surgery where appropriate). Use should be informed, time-limited, and coordinated with primary medical care.

Why vendor quality drives HGH Fragment 176-191 side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

HGH Fragment 176-191 side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .